Cambrex Co. (CBM) Shares Sold by Suffolk Capital Management …
Suffolk Capital Management LLC cut its stake in shares of Cambrex Co. (NYSE:CBM) by 22.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,546 shares of the company s stock after selling 12,554 shares during the period. Suffolk Capital Management LLC owned 0.14% of Cambrex worth $2,098,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Boston Advisors raised its stake in Cambrex by 1.4% in the fourth quarter. Boston Advisors now owns 17,002 shares of the company s stock valued at $801,000 after buying an additional 240 shares during the last quarter. Capital Fund Management S.A. bought a new stake in Cambrex during the fourth quarter valued at about $805,000. Sheets Smith Wealth Management raised its stake in Cambrex by 25.0% in the fourth quarter. Sheets Smith Wealth Management now owns 21,389 shares of the company s stock valued at $1,007,000 after buying an additional 4,283 shares during the last quarter. Hanseatic Management Services Inc. raised its stake in Cambrex by 101.4% in the fourth quarter. Hanseatic Management Services Inc. now owns 23,738 shares of the company s stock valued at $1,118,000 after buying an additional 11,953 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Cambrex by 5.3% in the fourth quarter. Rhumbline Advisers now owns 39,446 shares of the company s stock valued at $1,858,000 after buying an additional 1,975 shares during the last quarter. Shares of Cambrex Co. (NYSE:CBM) opened at 41.59 on Wednesday. Cambrex Co. has a 52 week low of $29.50 and a 52 week high of $55.60. The company has a market capitalization of $1.32 billion and a price-to-earnings ratio of 23.62. The company s 50 day moving average price is $37.43 and its 200-day moving average price is $44.29. Cambrex (NYSE:CBM) last released its quarterly earnings results on Tuesday, February 9th. The company reported $0.54 earnings per share for the quarter, missing analysts consensus estimates of $0.83 by $0.29. The company earned $156.90 million during the quarter, compared to the consensus estimate of $152.94 million. The company s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same period last year, the firm earned $0.89 earnings per share. Analysts anticipate that Cambrex Co. will post $2.48 earnings per share for the current fiscal year.
Several research firms have recently issued reports on CBM. Zacks Investment Research raised Cambrex from a hold rating to a buy rating and set a $41.00 price objective for the company in a research note on Friday, February 12th. Singular Research lowered their price objective on Cambrex from $63.00 to $60.00 and set a buy rating for the company in a research note on Thursday, February 11th. Finally, Sidoti initiated coverage on Cambrex in a research note on Monday, February 1st. They set a buy rating and a $60.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average price target of $54.33. In other Cambrex news, CEO Steven M. Klosk sold 39,542 shares of the business s stock in a transaction that occurred on Thursday, February 11th. The stock was sold at an average price of $36.20, for a total transaction of $1,431,420.40. Following the completion of the sale, the chief executive officer now directly owns 133,328 shares in the company, valued at approximately $4,826,473.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Shawn Cavanagh sold 18,342 shares of the business s stock in a transaction that occurred on Thursday, February 11th. The stock was sold at an average price of $36.13, for a total value of $662,696.46. Following the sale, the chief operating officer now owns 17,658 shares of the company s stock, valued at $637,983.54. The disclosure for this sale can be found here. Cambrex Corporation (NYSE:CBM) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies.
Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It’s time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).
Receive News & Ratings for Cambrex Co. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cambrex Co. and related companies with MarketBeat.com’s FREE daily email newsletter.
- ^ NYSE:CBM (www.marketbeat.com)
- ^ Zacks Investment Research (www.zacks.com)
- ^ this link (www.sec.gov)
- ^ here (www.sec.gov)
- ^ NYSE:CBM (www.marketbeat.com)
- ^ Compare brokers at a glance in the InvestorPlace Broker Center (Click Here) (investorplace.com)
- ^ MarketBeat.com’s FREE daily email newsletter (www.thevistavoice.org)